Drug Profile
FE 999309
Alternative Names: FE-999309Latest Information Update: 05 Sep 2018
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Class Urologics
- Mechanism of Action Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 05 Sep 2018 Discontinued - Phase-II for Overactive bladder (unspecified route) (Ferring Pharmaceuticals pipeline, September 2018)
- 10 Aug 2015 Phase-II clinical trials in Overactive bladder (unspecified route)